Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

38 questions · 38 findings · 8 reviews · Kidney and Transplant

No studies found 11 · 28.9%GRADE not reported 2 · 5.3%Very low 3 · 7.9%Low 22 · 57.9%Moderate 0 · 0%High 0 · 0%

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Death (all causes) · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Death (all causes) · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin receptor blockers (ARB) alone showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Death (all causes) · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in all‐cause death Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in cardiovascular death Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

More intensive vs less intensive insulin therapy

Death: unknown time frame · pre‐existing and new‐onset diabetes in kidney transplant recipients

It is very uncertain whether more intensive changes death (any cause) Time frame: 1 to 5 years compared with less intensive insulin therapy (very low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Death (all causes) · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs another ARB

Death (all causes) · people with diabetes and kidney disease

It is very uncertain whether angiotensin receptor blocker (ARB) changes all‐cause death Median compared with another ARB (very low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Death (all causes) · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors showed no clear difference in all‐cause death Median compared with placebo or no treatment (low certainty).

1 finding from 1 review